House Bill Proposes 12-Year Exclusivity for FDA-Approved Botanical Drugs

A bipartisan House proposal would grant newly approved botanical drugs a 12-year market-exclusivity period, potentially improving financing incentives for cannabinoid and other plant-derived medicines. Oklahoma cannabis operators should watch the bill because it could attract pharmaceutical capital while widening the gap between FDA-approved products and state-market cannabis.